Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. (49/158)

 (+info)

Cyclooxygenase-2 expression is not a marker of poor survival in lung cancer. (50/158)

OBJECTIVE: Cyclooxygenase-2 (COX-2) has been claimed to play role in carcinogenesis and be related to a bad prognosis in tumours. The aim of this study was to investigate the relationship between COX-2 expression and clinical and pathological parameters in early and advanced stage lung cancer patients. MATERIALS AND METHODS: A total of 73 patients with lung cancer (27 adenocarcinomas, 33 squamous cell carcinomas, 4 large cell carcinomas and 9 small cell cancer) were analysed retrospectively. COX-2 expression was evaluated by immunohistochemistry in resection materials or lung biopsies. Tumor cells demonstrating more intense staining than smooth muscle and endothelial cells were recorded as COX-2 positive. We investigated the correlation between increased COX-2 expression and histological type of the tumor, the stage of the disease and survival. RESULTS: COX-2 expression was observed in 55% of the adenocarcinomas, 45% of the squamous cell carcinomas and 22% of the small cell carcinomas. No correlation was apparent between COX-2 expression and disease stage, histological type and the survival. CONCLUSION: The results of this study do not support COX-2 expression as an independent prognostic factor in lung cancer. However, since results of the literature are different, further studies made in larger series are needed.  (+info)

Cancer-related fatigue in women with breast cancer: outcomes of a 5-year prospective cohort study. (51/158)

 (+info)

Adjuvant and neoadjuvant treatment in pancreatic cancer. (52/158)

 (+info)

Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. (53/158)

 (+info)

Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. (54/158)

 (+info)

Gastric ulceration following oesophageal stent migration complicating surgical management of oesophageal cancer. (55/158)

 (+info)

Preoperative chemoradiotherapy for esophageal or junctional cancer. (56/158)

 (+info)